Bank of New York Mellon
AVIR icon

Bank of New York Mellon’s Atea Pharmaceuticals AVIR Stock Holding History

Bank of New York Mellon’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$881K Buy
189,452
+3,647
+2% +$18.1K ﹤0.01% 3442
2026
Q1 		$1,000K Sell
185,805
-12,658
-6% -$58.1K ﹤0.01% 3206
2025
Q4 		$709K Sell
198,463
-9,019
-4% -$28.7K ﹤0.01% 3434
2025
Q3 		$602K Buy
207,482
+7,331
+4% +$25K ﹤0.01% 3494
2025
Q2 		$721K Sell
200,151
-2,965
-1% -$8.84K ﹤0.01% 3307
2025
Q1 		$607K Sell
203,116
-8,914
-4% -$27.8K ﹤0.01% 3351
2024
Q4 		$710K Sell
212,030
-660
-0.3% -$2.19K ﹤0.01% 3340
2024
Q3 		$713K Sell
212,690
-53,494
-20% -$194K ﹤0.01% 3318
2024
Q2 		$881K Buy
266,184
+26,627
+11% +$99.3K ﹤0.01% 3274
2024
Q1 		$968K Sell
239,557
-15,731
-6% -$61.6K ﹤0.01% 3170
2023
Q4 		$779K Sell
255,288
-66,120
-21% -$200K ﹤0.01% 3322
2023
Q3 		$964K Buy
321,408
+103
+0% +$350 ﹤0.01% 3176
2023
Q2 		$1.2M Buy
321,305
+11,746
+4% +$44K ﹤0.01% 3100
2023
Q1 		$1.04M Sell
309,559
-10,987
-3% -$44.6K ﹤0.01% 3117
2022
Q4 		$1.54M Buy
320,546
+13,690
+4% +$69.3K ﹤0.01% 2988
2022
Q3 		$1.75M Buy
306,856
+36,812
+14% +$282K ﹤0.01% 2931
2022
Q2 		$1.92M Sell
270,044
-6,682
-2% -$45.6K ﹤0.01% 2851
2022
Q1 		$2M Sell
276,726
-1,067
-0.4% -$7.25K ﹤0.01% 2946
2021
Q4 		$2.48M Buy
277,793
+18,519
+7% +$289K ﹤0.01% 2861
2021
Q3 		$9.09M Buy
259,274
+62,999
+32% +$1.75M ﹤0.01% 2180
2021
Q2 		$4.22M Buy
196,275
+152,038
+344% +$4.57M ﹤0.01% 2569
2021
Q1 		$2.73M Buy
44,237
+7,418
+20% +$501K ﹤0.01% 2747
2020
Q4 		$1.54M Buy
+36,819
New +$1.19M ﹤0.01% 2991

Other funds holding AVIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
AI
Auour Investments Woburn, Massachusetts $349M AUM 13.68% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's AVIR Position: Q2 2026 in Review

Bank of New York Mellon increased its Atea Pharmaceuticals (AVIR) stake by 2% in Q2 2026, buying an estimated $18.1K and bringing the position to 189,452 shares worth $881K. The position accounts for ﹤0.01% of the portfolio, ranked #3442.

Bank of New York Mellon first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $9.09M in Q3 2021. 40 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Bank of New York Mellon held 189,452 shares of Atea Pharmaceuticals worth $881K as of Q2 2026.
  • Bank of New York Mellon bought 3,647 Atea Pharmaceuticals shares in Q2 2026, an estimated $18.1K.
  • Atea Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3442 holding.
  • Bank of New York Mellon first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Bank of New York Mellon's Atea Pharmaceuticals position peaked at $9.09M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.